Cognitive impairment in childhood onset epilepsy: up-to-date information about its causes

Eun-Hee Kim1, Tae-Sung Ko2

  • 1Department of Pediatrics, CHA Gangnam Medical Center, CHA University, Seoul, Korea.

Insights

Childhood epilepsy negatively impacts cognitive development. This review examines key epilepsy-related factors contributing to cognitive impairment in children, highlighting the need for clearer delineation of their impact.

Area of Science:

  • Pediatric Neurology
  • Neurodevelopmental Disorders
  • Epileptology

Background:

  • Cognitive impairment is a significant consequence of childhood-onset epilepsy, affecting neurodevelopment and social outcomes.
  • The etiology of cognitive impairment in epilepsy is multifactorial, involving epilepsy type, onset age, seizure frequency, duration, and treatment.
  • Emerging evidence suggests shared neurobiological mechanisms between epilepsy and cognitive comorbidities, evidenced by pre-epilepsy cognitive deficits and early brain alterations.

Purpose of the Study:

  • To review and delineate the significant contributors to cognitive impairment in children with epilepsy.
  • To clarify the impact of cognitive comorbidity and the independent contribution of various epilepsy-related factors.

Main Methods:

  • Literature review of studies on cognitive impairment in childhood-onset epilepsy.
  • Analysis of factors including epilepsy type, etiology, age at onset, seizure characteristics, and treatment.
  • Synthesis of findings on neurobiological mechanisms and clinical impact.

Main Results:

  • Epilepsy-related factors such as epilepsy type, etiology, age at onset, seizure frequency, duration, and treatment are crucial contributors.
  • Antecedent cognitive impairment and early brain alterations suggest common underlying neurobiology.
  • The precise impact and independent contributions of these factors require further delineation.

Conclusions:

  • Understanding the multifactorial contributors to cognitive impairment in childhood epilepsy is essential for improving patient outcomes.
  • Further research is needed to precisely quantify the independent impact of each factor.
  • Targeted interventions addressing specific epilepsy-related factors may mitigate cognitive deficits in affected children.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.0K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
913
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
3.0K